Immatics N.V.
Immatics Biotechnologies GmbH
General information
Immatics N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Baden-Württemberg
Germany
Contact person: Harpreet Singh, Chief Executive Officer
Company main phone: +49 (7071) 53970
Company main fax: +49 (7071) 5397900
Website: https://www.immatics.com
Paul-Ehrlich-Straße 15
72076 Tübingen, Baden-Württemberg
Germany
Contact person: Harpreet Singh, Chief Executive Officer
Company main phone: +49 (7071) 53970
Company main fax: +49 (7071) 5397900
Website: https://www.immatics.com
| Year founded: | 2000 |
| Source of foundation: | Spin-off from university |
| Name of foundation source: | H.G. Rammensee's laboratory at the University of Tübingen, Germany |
| No. of employees: |
Worldwide: 432 |
Corporate description / mission:
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The company is developing targeted TCR-based immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) consisting of autologous (ACTengine®) or allogeneic (ACTallo®) product classes and antibody-like TCR Bispecifics, also called T cell Engaging Receptors (TCER®).
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The company is developing targeted TCR-based immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) consisting of autologous (ACTengine®) or allogeneic (ACTallo®) product classes and antibody-like TCR Bispecifics, also called T cell Engaging Receptors (TCER®).
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2020
Headquarters: HQ: Yes
IPO (year): 2020
Remarks on ownership / listings
In July 2020, Immatics started trading on NASDAQ as a result of a business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA; or “Arya”), a special purpose acquisition, sponsored by Perceptive Advisors.
In 2015, Immatics and MD Anderson Cancer Center launched Immatics US, Inc. in Houston Texas.
In July 2020, Immatics started trading on NASDAQ as a result of a business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA; or “Arya”), a special purpose acquisition, sponsored by Perceptive Advisors.
In 2015, Immatics and MD Anderson Cancer Center launched Immatics US, Inc. in Houston Texas.
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 7 | |
| Phase I: | 4 | |
| Phase II: | 1 |
Description of products:
ACTengine® IMA203 (PRAME),
ACTallo® IMA30x,
TCER® IMA401 (MAGEA4/8), ect.
ACTengine® IMA203 (PRAME),
ACTallo® IMA30x,
TCER® IMA401 (MAGEA4/8), ect.
Special IP situation:
The XPRESIDENT technology is protected by granted patents and patent applications.
The XPRESIDENT technology is protected by granted patents and patent applications.
Technology used:
XPRESIDENT™
XCEPTOR®
XPRESIDENT™
XCEPTOR®
Financing details
Fiscal year (end of) 2023
| Revenues: | USD 58.42M | |
| R&D expenses: | USD 128.39M | |
| Cash: | USD 236.39M |
| Total liabilities: | USD 308.24M | |
| No. of shares: | 102'985'000 | |
| Market cap. / valuation: | USD 1'092.67M |
Collaborations & Clients
Partnering strategy / collaborations:
Amgen
MDACC
MorphoSys
Roche
Genmab
Amgen
MDACC
MorphoSys
Roche
Genmab
© 2024 Biotechgate by Venture Valuation